Serum free light chains and multiple myeloma: Is it time to extend their application?

Abstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.

Bibliographic Details
Main Authors: Uros Markovic, Valerio Leotta, Daniele Tibullo, Rachele Giubbolini, Alessandra Romano, Vittorio Del Fabro, Nunziatina Laura Parrinello, Maria Teresa Cannizzaro, Francesco Di Raimondo, Concetta Conticello
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Clinical Case Reports
Subjects:
Online Access:https://doi.org/10.1002/ccr3.2636
_version_ 1828443194326515712
author Uros Markovic
Valerio Leotta
Daniele Tibullo
Rachele Giubbolini
Alessandra Romano
Vittorio Del Fabro
Nunziatina Laura Parrinello
Maria Teresa Cannizzaro
Francesco Di Raimondo
Concetta Conticello
author_facet Uros Markovic
Valerio Leotta
Daniele Tibullo
Rachele Giubbolini
Alessandra Romano
Vittorio Del Fabro
Nunziatina Laura Parrinello
Maria Teresa Cannizzaro
Francesco Di Raimondo
Concetta Conticello
author_sort Uros Markovic
collection DOAJ
description Abstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.
first_indexed 2024-12-10T21:25:41Z
format Article
id doaj.art-657fa85075444633b56e89ba4c07bb88
institution Directory Open Access Journal
issn 2050-0904
language English
last_indexed 2024-12-10T21:25:41Z
publishDate 2020-04-01
publisher Wiley
record_format Article
series Clinical Case Reports
spelling doaj.art-657fa85075444633b56e89ba4c07bb882022-12-22T01:33:00ZengWileyClinical Case Reports2050-09042020-04-018461762410.1002/ccr3.2636Serum free light chains and multiple myeloma: Is it time to extend their application?Uros Markovic0Valerio Leotta1Daniele Tibullo2Rachele Giubbolini3Alessandra Romano4Vittorio Del Fabro5Nunziatina Laura Parrinello6Maria Teresa Cannizzaro7Francesco Di Raimondo8Concetta Conticello9UOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyDepartment of Biomedical and Biotechnological Sciences University of Catania Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyRadiology via Santa Sofia 78 AOU Policlinico‐"Vittorio Emanuele" Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyAbstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.https://doi.org/10.1002/ccr3.2636disease progressionextramedullary relapsemultiple myelomaserological markersserum free light chains
spellingShingle Uros Markovic
Valerio Leotta
Daniele Tibullo
Rachele Giubbolini
Alessandra Romano
Vittorio Del Fabro
Nunziatina Laura Parrinello
Maria Teresa Cannizzaro
Francesco Di Raimondo
Concetta Conticello
Serum free light chains and multiple myeloma: Is it time to extend their application?
Clinical Case Reports
disease progression
extramedullary relapse
multiple myeloma
serological markers
serum free light chains
title Serum free light chains and multiple myeloma: Is it time to extend their application?
title_full Serum free light chains and multiple myeloma: Is it time to extend their application?
title_fullStr Serum free light chains and multiple myeloma: Is it time to extend their application?
title_full_unstemmed Serum free light chains and multiple myeloma: Is it time to extend their application?
title_short Serum free light chains and multiple myeloma: Is it time to extend their application?
title_sort serum free light chains and multiple myeloma is it time to extend their application
topic disease progression
extramedullary relapse
multiple myeloma
serological markers
serum free light chains
url https://doi.org/10.1002/ccr3.2636
work_keys_str_mv AT urosmarkovic serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT valerioleotta serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT danieletibullo serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT rachelegiubbolini serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT alessandraromano serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT vittoriodelfabro serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT nunziatinalauraparrinello serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT mariateresacannizzaro serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT francescodiraimondo serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication
AT concettaconticello serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication